Biomarkers of intestinal fibrosis – one step towards clinical trials for stricturing inflammatory bowel disease

Paolo Giuffrida, Massimo Pinzani, Gino R. Corazza, Antonio Di Sabatino

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Intestinal fibrosis, caused by an excessive deposition of extracellular matrix components, and subsequent stricture development are a common complication of inflammatory bowel disease. However, currently there are no biomarkers which reliably predict the risk of developing intestinal strictures or identify early stages of fibrosis prior to clinical symptoms. Candidate biomarkers of intestinal fibrosis, including gene variants (i.e. nucleotide-binding oligomerization domain-2 gene), serum microRNAs (miR-19, miR-29), serum extracellular matrix proteins (i.e. collagen, fibronectin) or enzymes (i.e. tissue inhibitor of matrix metalloproteinase-1), serum growth factors (i.e. basic fibroblast growth factor, YKL-40), serum anti-microbial antibodies (i.e. anti-Saccharomyces cerevisiae) and circulating cells (i.e. fibrocytes) have shown conflicting results on relatively heterogeneous patients’ cohorts, and none of them was proven to be strictly specific for fibrostenosis, but rather predictive of a disease disabling course. In this review we critically reassess the diagnostic and prognostic value of serum biomarkers of intestinal fibrosis in inflammatory bowel disease.

Original languageEnglish
Pages (from-to)523-530
Number of pages8
JournalUnited European Gastroenterology Journal
Volume4
Issue number4
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Inflammatory Bowel Diseases
Fibrosis
Biomarkers
Clinical Trials
Serum
Pathologic Constriction
Matrix Metalloproteinase 1
Tissue Inhibitor of Metalloproteinase-1
Extracellular Matrix Proteins
Fibroblast Growth Factor 2
MicroRNAs
Fibronectins
Genes
Extracellular Matrix
Saccharomyces cerevisiae
Blood Proteins
Anti-Idiotypic Antibodies
Intercellular Signaling Peptides and Proteins
Collagen
Nucleotides

Keywords

  • Anti-microbial antibody
  • Crohn’s disease
  • extracellular matrix
  • growth factor
  • microRNA

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Biomarkers of intestinal fibrosis – one step towards clinical trials for stricturing inflammatory bowel disease. / Giuffrida, Paolo; Pinzani, Massimo; Corazza, Gino R.; Di Sabatino, Antonio.

In: United European Gastroenterology Journal, Vol. 4, No. 4, 01.08.2016, p. 523-530.

Research output: Contribution to journalReview article

@article{bb02cd96e8334758ace41c805b025726,
title = "Biomarkers of intestinal fibrosis – one step towards clinical trials for stricturing inflammatory bowel disease",
abstract = "Intestinal fibrosis, caused by an excessive deposition of extracellular matrix components, and subsequent stricture development are a common complication of inflammatory bowel disease. However, currently there are no biomarkers which reliably predict the risk of developing intestinal strictures or identify early stages of fibrosis prior to clinical symptoms. Candidate biomarkers of intestinal fibrosis, including gene variants (i.e. nucleotide-binding oligomerization domain-2 gene), serum microRNAs (miR-19, miR-29), serum extracellular matrix proteins (i.e. collagen, fibronectin) or enzymes (i.e. tissue inhibitor of matrix metalloproteinase-1), serum growth factors (i.e. basic fibroblast growth factor, YKL-40), serum anti-microbial antibodies (i.e. anti-Saccharomyces cerevisiae) and circulating cells (i.e. fibrocytes) have shown conflicting results on relatively heterogeneous patients’ cohorts, and none of them was proven to be strictly specific for fibrostenosis, but rather predictive of a disease disabling course. In this review we critically reassess the diagnostic and prognostic value of serum biomarkers of intestinal fibrosis in inflammatory bowel disease.",
keywords = "Anti-microbial antibody, Crohn’s disease, extracellular matrix, growth factor, microRNA",
author = "Paolo Giuffrida and Massimo Pinzani and Corazza, {Gino R.} and {Di Sabatino}, Antonio",
year = "2016",
month = "8",
day = "1",
doi = "10.1177/2050640616640160",
language = "English",
volume = "4",
pages = "523--530",
journal = "United European Gastroenterology Journal",
issn = "2050-6406",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Biomarkers of intestinal fibrosis – one step towards clinical trials for stricturing inflammatory bowel disease

AU - Giuffrida, Paolo

AU - Pinzani, Massimo

AU - Corazza, Gino R.

AU - Di Sabatino, Antonio

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Intestinal fibrosis, caused by an excessive deposition of extracellular matrix components, and subsequent stricture development are a common complication of inflammatory bowel disease. However, currently there are no biomarkers which reliably predict the risk of developing intestinal strictures or identify early stages of fibrosis prior to clinical symptoms. Candidate biomarkers of intestinal fibrosis, including gene variants (i.e. nucleotide-binding oligomerization domain-2 gene), serum microRNAs (miR-19, miR-29), serum extracellular matrix proteins (i.e. collagen, fibronectin) or enzymes (i.e. tissue inhibitor of matrix metalloproteinase-1), serum growth factors (i.e. basic fibroblast growth factor, YKL-40), serum anti-microbial antibodies (i.e. anti-Saccharomyces cerevisiae) and circulating cells (i.e. fibrocytes) have shown conflicting results on relatively heterogeneous patients’ cohorts, and none of them was proven to be strictly specific for fibrostenosis, but rather predictive of a disease disabling course. In this review we critically reassess the diagnostic and prognostic value of serum biomarkers of intestinal fibrosis in inflammatory bowel disease.

AB - Intestinal fibrosis, caused by an excessive deposition of extracellular matrix components, and subsequent stricture development are a common complication of inflammatory bowel disease. However, currently there are no biomarkers which reliably predict the risk of developing intestinal strictures or identify early stages of fibrosis prior to clinical symptoms. Candidate biomarkers of intestinal fibrosis, including gene variants (i.e. nucleotide-binding oligomerization domain-2 gene), serum microRNAs (miR-19, miR-29), serum extracellular matrix proteins (i.e. collagen, fibronectin) or enzymes (i.e. tissue inhibitor of matrix metalloproteinase-1), serum growth factors (i.e. basic fibroblast growth factor, YKL-40), serum anti-microbial antibodies (i.e. anti-Saccharomyces cerevisiae) and circulating cells (i.e. fibrocytes) have shown conflicting results on relatively heterogeneous patients’ cohorts, and none of them was proven to be strictly specific for fibrostenosis, but rather predictive of a disease disabling course. In this review we critically reassess the diagnostic and prognostic value of serum biomarkers of intestinal fibrosis in inflammatory bowel disease.

KW - Anti-microbial antibody

KW - Crohn’s disease

KW - extracellular matrix

KW - growth factor

KW - microRNA

UR - http://www.scopus.com/inward/record.url?scp=85007323654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007323654&partnerID=8YFLogxK

U2 - 10.1177/2050640616640160

DO - 10.1177/2050640616640160

M3 - Review article

AN - SCOPUS:85007323654

VL - 4

SP - 523

EP - 530

JO - United European Gastroenterology Journal

JF - United European Gastroenterology Journal

SN - 2050-6406

IS - 4

ER -